Company Description
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.
Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.
The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
| Country | United States |
| Founded | 2008 |
| IPO Date | Dec 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Mark Iwicki |
Contact Details
Address: 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 United States | |
| Phone | 678 392 3419 |
| Website | inhibikase.com |
Stock Details
| Ticker Symbol | IKT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001750149 |
| CUSIP Number | 45719W106 |
| ISIN Number | US45719W2052 |
| Employer ID | 26-3407249 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark T. Iwicki | Chief Executive Officer |
| Dr. Christopher H. Cabell FACC, M.D., MHS | President and Head of Research and Development |
| Garth Lees-Rolfe CPA | Chief Financial Officer |
| Dr. John Adams Ph.D. | Chief Scientific Officer |
| Dr. Surendra Singh Ph.D. | Head of Chemistry, Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 16, 2025 | EFFECT | Notice of Effectiveness |